(Q53132134)

11 May 2018

title

Are biomarkers harmful to recruitment and retention in Alzheimer's disease clinical trials? An international perspective. (English)

1 reference

11 May 2018

1 reference

1 reference

H Hampel

1

1 reference

11 May 2018

D Prvulovic

series ordinal

2

1 reference

11 May 2018

publication date

1 April 2012

1 reference

11 May 2018

The Journal of Nutrition, Health and Aging

published in

1 reference

11 May 2018

volume

16

1 reference

11 May 2018

issue

4

1 reference

11 May 2018

page(s)

346-348

1 reference

11 May 2018

https://scigraph.springernature.com/pub.10.1007/s12603-012-0021-4

exact match

0 references

cites work

CSF biomarker utilisation and ethical considerations of biomarker assisted diagnosis and research in dementia: perspectives from within the European Alzheimer's Disease Consortium (EADC).

1 reference

https://api.crossref.org/works/10.1007%2FS12603-012-0021-4

The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-012-0021-4

Cholinergic markers in elderly patients with early signs of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-012-0021-4

Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-012-0021-4

Revising the definition of Alzheimer's disease: a new lexicon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-012-0021-4

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-012-0021-4

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-012-0021-4

Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-012-0021-4

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-012-0021-4

Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-012-0021-4

A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-012-0021-4

Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-012-0021-4

What can be inferred from the interruption of the semagacestat trial for treatment of Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-012-0021-4

Effect of memantine on resting state default mode network activity in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-012-0021-4

Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-012-0021-4

Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-012-0021-4

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-012-0021-4

Diagnostic power of default mode network resting state fMRI in the detection of Alzheimer's disease

21 January 2018

1 reference

12 December 2020

Low incidence of post-lumbar puncture headache in 1,089 consecutive memory clinic patients

1 reference

12 December 2020

Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance

1 reference

12 December 2020

Cerebrospinal fluid biomarkers for Alzheimer’s disease: diagnostic performance in a homogeneous mono-center population.

1 reference

12 December 2020

Biomarkers in clinical trials for neurodegenerative diseases: Regulatory perspectives and requirements

1 reference

12 December 2020

Recent developments of functional magnetic resonance imaging research for drug development in Alzheimer's disease

1 reference

12 December 2020

10.1007/S12603-012-0021-4

Identifiers

DOI

1 reference

11 May 2018

1 reference

11 May 2018